Topics

Clinical Trials About "Autonomic Regulation in Prader-Willi Syndrome" RSS

22:43 EST 17th January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Autonomic Regulation in Prader-Willi Syndrome" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Autonomic Regulation in Prader-Willi Syndrome" on BioPortfolio

We have published hundreds of Autonomic Regulation in Prader-Willi Syndrome news stories on BioPortfolio along with dozens of Autonomic Regulation in Prader-Willi Syndrome Clinical Trials and PubMed Articles about Autonomic Regulation in Prader-Willi Syndrome for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Autonomic Regulation in Prader-Willi Syndrome Companies in our database. You can also find out about relevant Autonomic Regulation in Prader-Willi Syndrome Drugs and Medications on this site too.

Showing "Autonomic Regulation Prader Willi Syndrome" Clinical Trials 1–25 of 9,300+

Extremely Relevant

Autonomic Regulation in Prader-Willi Syndrome

To evaluate autonomic regulation in patients with Prader-Willi syndrome with sleep-disordered breathing.


Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls

The purpose of the study is to find out if people with Prader-Willi syndrome have a difference in the protein which changes inactive cortisone to the active stress hormone cortisol.

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).


Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

The objective of this study is to collect data on tolerance and effects of early treatment with oxytocin in children with Prader Willi Syndrome aged from 3 to 4 years and to compare these infants with not treated age-matched infants with Prader Willi Syndrome.

Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

The purpose of this is study is to evaluate the long term safety of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.

Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome

The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC) injectable formulation of RM-493 in obese subjects with Prader-Willi syndrome on tolerability, weight loss and hyperphagia-related behavior. The study drug (RM-493 and placebo) will be administered in a blinded fashion.

A Study of GLWL-01 in Patients With Prader-Willi Syndrome

The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the treatment of patients with Prader-Willi Syndrome (PWS).

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.

Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome

Prader-Willi syndrome (PWS) is a genetic disorder usually caused by the deletion of a specific gene. One of the symptoms of PWS is self-injurious behavior (SIB); a common form of SIB in PWS patients is skin picking. The injury may be severe enough to require frequent medical attention. This trial will evaluate SIB in individuals with PWS and will test the effectiveness of the drug topiramate to control SIB.

Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome

Ask the 4 carers of children with Prader-willi syndrome to disclose their experiences and difficulties for searching better management and intervention

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

The purpose of this study is to compare the change in suck and swallow competency from baseline to day 5 with intranasal oxytocin spray vs placebo in infants/children with Prader-Willi Syndrome who are in nutritional phase 1a. Videofluoroscopic swallow studies will be performed on treatment day 1 and on the day following treatment day 5

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin). This study will also evaluate the safety and tolerability of LV-101.

Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).

A Double Blind, Placebo Controlled, Fixed-Flexible, Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects.

Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome

The investigator thinks that the oxytocin (OT) can improve durably and significantly the behavior disorders and thus the socialization but also the satisfaction and could thus be an interesting therapeutic alternative for the patients presenting a Prader-Willi Syndrome (SPW). Although today several studies demonstrated the effects of the OT in various domains of the behavior, the investigator do not know either its specificity of action about the cerebral level, or its duration...

Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome

Prader-Willi syndrome (PWS) is a genetic disorder characterized by childhood-onset obesity and endocrine dysfunction that leads to cardiovascular disability and early death within the first 3 decades of life.To assess the significance of risk factors for future disabilities, carotid artery intima-media thickness (IMT) was measured and correlated with known atherosclerotic risk factors in 27 children with PWS and 24 age-, sex-, and body mass index (BMI)-adjusted controls.

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study.

Register of Patients With Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) is a rare syndrome with a prevalence of 15 to 20 000 at birth. PWS represents a large fraction of mental retardation syndromes due to a genetic cause and the most frequent cause of genetic obesity. The majority of the patients are seen by paediatricians. This syndrome is responsible for severe physical, psychological and social impairments. The diversity and the severity of the manifestations of this disease explain the requirement of multidis...

Therapeutic Effects of Hippotherapy in Children With Prader-Willi Syndrome

This study evaluates the therapeutic effects of hippotherapy in children with Prader-Willi syndrome. Half of children will participate in hippotherapy for 15 weeks (30 minutes per sessions, twice a week, total 30 sessions, private lesson), while the other half will not receive hippotherapy.

Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi Syndrome

The primary objectives of this study are to assess the efficacy of Cannabidiol Oral Solution on hyperphagia-related behavior in subjects with Prader-Willi Syndrome (PWS), and to assess the efficacy of Cannabidiol Oral Solution on body weight in subjects with PWS.

Growth Hormone Use in Adults With Prader-Willi Syndrome

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months.

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome

The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in patients with Prader-Willi Syndrome.

Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) is a multisystemic genetic disease characterized by hypotonia, mental retardation, hyperphagia, and uncontrollable hunger due to hypothalamic dysfunction, caused by dysregulation of genes located in chromosome 15q11-q13. The goal of this study is to evaluate the effects of Transcranial Direct Current Stimulation (tDCS) on hyperphagia and behavior in PWS. Forty children and adolescents (11-24 years) with clinical and cytogenetic-molecular diagnosis of...

Mitochondrial Complex I Dysfunction in PWS

Prader-Willi Syndrome (PWS) is characterized by profound infantile hypotonia, growth delay, cognitive impairment, muscle weakness and exercise intolerance. Studies have suggested that a defect in energy metabolism, yet to be clarified, may be involved in its pathogenesis. Many PWS patients have received Coenzyme Q10, but the rationale for this and objective impact on cellular metabolism has not been clarified.


More From BioPortfolio on "Autonomic Regulation in Prader-Willi Syndrome"

Quick Search